Voyager Therapeutics, Inc. (VYGR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VYGR Revenue Growth
Revenue Breakdown (FY 2017)
VYGR's revenue distribution by segment and geography for fiscal year 2017
By Product/Segment
VYGR Revenue Analysis (2014–2025)
As of May 8, 2026, Voyager Therapeutics, Inc. (VYGR) generated trailing twelve-month (TTM) revenue of $40.4 million, reflecting explosive growth of +144.3% year-over-year. The most recent quarter (Q4 2025) recorded $15.3 million in revenue, up 14.7% sequentially.
Looking at the longer-term picture, VYGR's 5-year compound annual growth rate (CAGR) stands at -25.1%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $250.0 million in 2023.
Revenue diversification analysis shows VYGR's business is primarily driven by Parkinsonprogram (100%). With over half of revenue concentrated in Parkinsonprogram, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SRPT (-2.2% YoY), RARE (+13.3% YoY), and FOLD (+20.0% YoY), VYGR has outperformed the peer group in terms of revenue growth. Compare VYGR vs SRPT →
VYGR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VYGRCurrent | $40M | +144.3% | -25.1% | -326.6% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% |
VYGR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $40.4M | -49.5% | $0 | - | $-131,844,000 | -326.6% |
| 2024 | $80.0M | -68.0% | $80.0M | 100.0% | $-83,287,000 | -104.1% |
| 2023 | $250.0M | +511.2% | $157.8M | 63.1% | $122.0M | 48.8% |
| 2022 | $40.9M | +9.3% | $-14,857,000 | -36.3% | $-50,837,000 | -124.3% |
| 2021 | $37.4M | -78.1% | $-36,372,000 | -97.2% | $-73,618,000 | -196.8% |
| 2020 | $171.1M | +63.9% | $62.4M | 36.4% | $27.4M | 16.0% |
| 2019 | $104.4M | +1270.1% | $-15,344,000 | -14.7% | $-51,679,000 | -49.5% |
| 2018 | $7.6M | -24.8% | $-57,286,000 | -751.9% | $-91,095,000 | -1195.6% |
| 2017 | $10.1M | -28.7% | $-52,125,000 | -514.3% | $-71,863,000 | -709.1% |
| 2016 | $14.2M | -18.0% | $-28,029,000 | -197.1% | $-41,299,000 | -290.4% |
See VYGR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VYGR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VYGR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVYGR — Frequently Asked Questions
Quick answers to the most common questions about buying VYGR stock.
Is VYGR's revenue growth accelerating or slowing?
VYGR revenue is accelerating at +144.3% year-over-year, exceeding the 5-year CAGR of -25.1%. TTM revenue reached $40M. Growth momentum has increased versus prior periods.
What is VYGR's long-term revenue growth rate?
Voyager Therapeutics, Inc.'s 5-year revenue CAGR of -25.1% reflects the sustained expansion pattern. Current YoY growth of +144.3% is above this long-term average.
How is VYGR's revenue distributed by segment?
VYGR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.